Notice of Proposed Sale · 144
Beta Bionics, Inc.
BBNXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- BETA BIONICS, INC.
- Issuer CIK
- 0001674632
- SEC file number
- 001-42491
- Phone
- 949-427-7785
- Person for whose account securities are to be sold
- Mark Hopman
- Relationships to issuer
- Officer
- Street
- 11 HUGHES
- City
- IRVINE
- State / country code
- CA
- Postal code
- 92618
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 5,327 | 103,423.71 | 45,123,368 | 09/02/2026 | NASDAQ | Morgan Stanley Smith Barney LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC
- Street
- 1 New York Plaza
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 09/01/2026 | Restricted Stock Units vesting under registered plan | Issuer | 5,327 | N | 09/01/2026 | Compensation for services rendered to Issuer |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Mark Hopman | Common Stock | 06/02/2026 | 5,329 | 67,183.24 |
| Mark Hopman | Common Stock | 06/04/2026 | 275 | 3,385.25 |
| Mark Hopman | Common Stock | 06/24/2026 | 1,258 | 18,880.44 |
Seller — prior-sale row 1, entry 1
- Name
- Mark Hopman
- Street
- c/o Beta Bionics, Inc.
- Street (continued)
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Seller — prior-sale row 2, entry 1
- Name
- Mark Hopman
- Street
- c/o Beta Bionics, Inc.
- Street (continued)
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Seller — prior-sale row 3, entry 1
- Name
- Mark Hopman
- Street
- c/o Beta Bionics, Inc.
- Street (continued)
- 11 Hughes
- City
- Irvine
- State / country code
- CA
- Postal code
- 92618
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
This is a sell-to-cover transaction for taxes owed related to recent vesting of stock unit awards granted by the Issuer.
Notice signature
- Notice date
- 09/03/2026
- Signed
- /s/ Stephen Feider, Attorney-in-Fact
Company context
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control an